Perhimpunan Dokter Paru Indonesia - Effect of weight loss on COPD-associated comorbidities in obese COPD
RSS Feed klikPDPI.com twitter PDPI Facebook Page - Kedokteran Paru & Respirologi Forum Respirologi (Umum) Foto Operasional web PDPI Foto Operasional web PDPI
Members
Untitled Document
News
1 2 3 4 5
Mitra Kerja
Video

Tutorial Aplikasi ISR

Bahaya Rokok Elektrik
 
Effect of weight loss on COPD-associated comorbidities in obese COPD





Netsanet Negewo1, Peter Gibson1,2, Lisa Wood1, Katherine Baines1 and Vanessa McDonald1,2
1Priority Research Centre for Healthy Lungs and Hunter Medical Research Institute, The University of Newcastle, New South Wales, NSWAustralia, 2Department of Respiratory and Sleep Medicine, John Hunter Hospital, New South Wales, NSWAustralia

Background: The effect of weight loss on COPD-associated comorbidities in obese COPD patients is unknown.

Aim: To test the hypothesis that an intervention targeting obesity could improve markers of comorbidities in obese COPD.

Method: A secondary analysis of a before-after clinical trial (McDonald, V.M. et al. Respirology 2016 doi:10.1111/resp.12746), where 28 obese COPD patients (BMI≥30kg/m2) completed a 12-week dietary restriction and resistance training, was performed. This abstract reports the change in comorbidity markers post-intervention.

Results: Mean (SD) age was 67.6 (6.3) years, 17 were males and FEV1% predicted was 61.6 (17.1)%. Mean BMI was 36.1 (4.5)kg/m2 at baseline and was reduced by 2.4kg/m2 (p<0.0001). The most common comorbidities included hypertension (53.6%), hyperlipidaemia (46.4%), depression (32.1%) and diabetes (14.3%). Weight loss improved cardio-metabolic markers and depression score, primarily in participants with elevated basal levels of these markers.

Conclusion: Weight loss with exercise training results in improvements in multiple markers of comorbidities in obese COPD.

Markers Pre? Post? p value
Total cholesterol (≥5.5mmol/L) n=7 6 (5.9,6.1) 5.4 (5.2,5.8) 0.03
Triglycerides (≥2mmol/L) n=5 2.28 (2.2,2.98) 1.8 (1.53,1.86) 0.04
Systolic BP (≥140mmHg) n=15 146 (143,151) 124 (122,145) 0.03
Diastolic BP (≥90mmHg) n=5 94 (91,94) 71 (67,80) 0.04
Fasting blood glucose (≥6.1mmol/L) n=6 6.45 (6.1,6.7) 5.5 (4.8,6) 0.03
Homeostasis Model Assessment-Insulin Resistance (≥1.4) n=8 2.4 (2.08,2.68) 1.55 (1.11,1.78) 0.02
Hospital Anxiety & Depression Scale-Depression Score (≥8) n=6 9 (8,11) 6 (4,7) 0.04
median (IQR)
Table 1
Effect of intervention in participant with elevated comorbidity markers at baseline

http://erj.ersjournals.com/content/48/suppl_60/PA643



PDPI Sulawesi Selatan & Utara. 01/03/17.



Halaman Siap Cetak  Halaman Siap Cetak

Kirimkan Pada Rekan  Kirimkan Pada Rekan
 

Free Web Counters

©2003 Perhimpunan Dokter Paru Indonesia
Privacy Policy  webmaster@klikpdpi.com


 
Intranet PDPI